Cleerly ISCHEMIA vs ElucidVivo A.3
AI Verdict
Choose Cleerly ISCHEMIA if…
Choose Cleerly ISCHEMIA if your primary goal is to non-invasively determine the likelihood of coronary artery ischemia at a vessel level and obtain a comprehensive characterization of coronary plaque from CCTA scans. This tool is ideal for physicians seeking to personalize diagnosis and treatment planning for patients with suspected heart disease by understanding both functional impairment and overall plaque burden.
View Cleerly ISCHEMIA →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability, including specific quantification of Lipid-Rich Necrotic Core (LRNC), from CT angiography. This system is particularly well-suited for stratifying atherosclerosis patients and optimizing treatment decisions based on precise, histology-validated insights into plaque vulnerability and characteristics.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Cleerly ISCHEMIA | ElucidVivo A.3 |
|---|---|---|
| Deployment | Web-based solution | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Cleerly ISCHEMIACleerly ISCHEMIA operates on a web-based platform with comprehensive interactive web-based reports, suggesting a modern and accessible user experience. Furthermore, its compliance with usability engineering standards and documented evaluations indicate a focus on user-friendly design.
Clinical Value
Cleerly ISCHEMIACleerly ISCHEMIA directly determines the likelihood of coronary artery ischemia at a vessel level and provides non-invasive FFR estimation, validated against invasive FFR. It has also demonstrated prognostic utility for future Major Adverse Cardiac Events (MACE), offering a more immediately actionable clinical impact for guiding treatment decisions.
Pricing & Value
TieBoth tools require direct contact for pricing, making a comparative assessment of cost impossible. However, both Cleerly ISCHEMIA and ElucidVivo A.3 have secured Category I CPTu00ae codes for their respective analyses, which significantly enhances their value proposition to providers through improved reimbursement potential.
Enterprise Readiness
Cleerly ISCHEMIACleerly ISCHEMIA explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA). Its deployment as a web-based platform with a clear data transfer mechanism via Cleerly Proxy and integration with PowerScribe via API demonstrates a well-defined and transparent enterprise strategy.
Innovation
ElucidVivo A.3While both leverage AI for advanced CCTA analysis, ElucidVivo A.3's innovation stands out in its objective quantification of specific arterial plaque components, such as Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications, which is uniquely validated against ground-truth histology. This provides a deeper and more precise understanding of plaque stability and vulnerability.
Support & Docs
Cleerly ISCHEMIACleerly ISCHEMIA provides explicit client support channels, including a dedicated form for technical support for existing users and specified operating hours (Monday-Friday, 10 am ET to 6 pm ET). This level of transparency and readily available support resources is not as evident for ElucidVivo A.3 based on the available information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Cleerly ISCHEMIA | ElucidVivo A.3 |
|---|---|---|
| Primary Purpose | Analyzes CCTA scans to non-invasively determine the likelihood of coronary artery ischemia at a vessel level, aiding physicians in personalized diagnosis and treatment planning for heart disease. | Provides quantitative analysis of arterial plaque composition and stability from CT angiography, assisting physicians in atherosclerosis patient stratification and optimizing treatment decisions. |
| Target Specialties | Cardiology, Radiology | Cardiology, Radiology, Vascular Surgery |
| Core Analysis Focus | AI-enabled CCTA analysis, vessel-level ischemia likelihood determination, coronary plaque characterization, stenosis severity assessment. | AI-powered quantitative analysis of arterial plaque, objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images, aids in stratifying patients with atherosclerosis. |
| FFR Estimation | Non-invasive fractional flow reserve (FFR) estimation | Derives fractional flow reserve (FFRct) based on vessel wall vasodilative capacity |
| Plaque Characterization | Coronary plaque characterization (volume, type, location) | Objectively quantifies Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications from CT images; visualizes lesion-level plaque composition; validated on ground-truth histology. |
| 3D Visualization | 3D digital models of coronary arteries | Provides 3D visualization of highlighted vessels; offers rotatable curved MPR vessel views and cross-sections. |
Videos
Demos, reviews, and walkthroughs featuring Cleerly ISCHEMIA and ElucidVivo A.3.
Frequently Asked Questions
More Comparisons
More matchups featuring Cleerly ISCHEMIA or ElucidVivo A.3
Backers
Who funded each tool's parent company.